Citadel Advisors
BCTXL

Citadel Advisors’s BriaCell Therapeutics Warrant BCTXL Stock Holding History

Citadel Advisors’s Portfolio BCTXL Stock Details BCTXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.05M Buy
+1,048,759
New +$1.11M ﹤0.01% 7550

Other funds holding BCTXL

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Citadel Advisors's BCTXL Position: Q1 2026 in Review

Citadel Advisors opened a new position in BriaCell Therapeutics Warrant (BCTXL) in Q1 2026: 1,048,759 shares worth $1.05M. The stake represents ﹤0.01% of the portfolio and ranks #7550 among its holdings.

15 funds tracked by Wall St. Rank hold BCTXL as of Q1 2026.

  • Citadel Advisors held 1,048,759 shares of BriaCell Therapeutics Warrant worth $1.05M as of Q1 2026.
  • BriaCell Therapeutics Warrant was a new Citadel Advisors position in Q1 2026.
  • BriaCell Therapeutics Warrant made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7550 holding.
  • 15 funds tracked by Wall St. Rank held BriaCell Therapeutics Warrant as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.